Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer.

World Journal of Urology
Stefan MachtensUdo Jonas

Abstract

Permanent interstitial brachytherapy represents the most conformal form of radiation therapy of the prostate and the number of patients with prostate cancers treated with permanent radioactive implants is increasing world wide. In the meanwhile long-term data on tumor control and treatment morbidity become available. Biochemical and clinical tumor control appears to be as effective as after radical prostatectomy or external beam radiation therapy in early prostate cancer. The risk of postreatment urinary incontinence and bowel dysfunction is low and erectile function can be preserved in the majority of patients. However, prostate brachytherapy requires a careful selection of patients as pretreatment factors predict for long-term outcome. The need for combined modality approaches in intermediate and high-risk patients remains controversely discussed. The continous refinement of intraoperative planning techniques and the elucidation of the etiology of urinary, sexual, and bowel dysfunction should result in further improvements in biochemical outcomes and decreased morbidity. Improved and standardized postimplantation evaluation will make outcome data more reliable and comparable.

References

Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·C C Ling
Dec 1, 1972·The Journal of Urology·W F WhitmoreH Grabstald
Apr 30, 1995·International Journal of Radiation Oncology, Biology, Physics·R G StockJ K DeWyngaert
May 15, 1995·International Journal of Radiation Oncology, Biology, Physics·K WallnerL Harrison
Mar 15, 1993·International Journal of Radiation Oncology, Biology, Physics·V E ArterberyZ Fuks
Jul 15, 1996·International Journal of Radiation Oncology, Biology, Physics·M DattoliS Wasserman
Apr 8, 1998·International Journal of Radiation Oncology, Biology, Physics·J J PreteP D Grimm
May 20, 1998·International Journal of Radiation Oncology, Biology, Physics·R G StockJ K DeWyngaert
Jun 17, 1998·The Journal of Urology·S I ZeitlinP Albert
Aug 27, 1998·International Journal of Radiation Oncology, Biology, Physics·F M WatermanA P Dicker
Mar 17, 1999·International Journal of Radiation Oncology, Biology, Physics·M R StoreyM Hauer-Jensen
Apr 7, 1999·International Journal of Radiation Oncology, Biology, Physics·G S MerrickH J Blatt
Jul 20, 1999·The Journal of Urology·N N Stone, R G Stock
Sep 7, 1999·International Journal of Radiation Oncology, Biology, Physics·D Y GelblumS Leibel
Feb 3, 2000·International Journal of Radiation Oncology, Biology, Physics·S NagY Yu
Mar 8, 2000·International Journal of Radiation Oncology, Biology, Physics·J C BlaskoW Cavanagh
Apr 12, 2000·International Journal of Radiation Oncology, Biology, Physics·G S MerrickA T Dorsey
Aug 5, 2000·International Journal of Radiation Oncology, Biology, Physics·D Y Gelblum, L Potters
Dec 6, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J C BlaskoW Cavanagh
Dec 6, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·D AshUNKNOWN EORTC Radiotherapy Group
May 31, 2001·International Journal of Radiation Oncology, Biology, Physics·K M SnyderN N Stone
Aug 3, 2001·International Journal of Radiation Oncology, Biology, Physics·L PottersM W Kattan
Aug 23, 2001·International Journal of Radiation Oncology, Biology, Physics·P D GrimmW Cavanagh
Jun 21, 2002·European Urology·N N Stone, R G Stock
Jun 21, 2002·European Urology·Richard G Stock, Nelson N Stone
Oct 25, 2003·International Journal of Radiation Oncology, Biology, Physics·John E SylvesterJudith A Malmgren
Apr 7, 2004·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Louis PottersPatrick A Kupelian
May 14, 2005·International Journal of Radiation Oncology, Biology, Physics·Gregory S MerrickZachariah A Allen

❮ Previous
Next ❯

Citations

Jul 4, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·F GuedeaM Ventura
Sep 1, 2009·Therapeutic Advances in Medical Oncology·Matthew A UhlmanLeon Sun
Mar 21, 2013·Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists·Hualin Zhang, David Beyer
Nov 4, 2009·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·J DoyenJ-M Hannoun-Lévi
Oct 3, 2008·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·J-M CossetL Chauveinc
Mar 13, 2008·Cancer Treatment Reviews·L MarignolD Hollywood
Oct 9, 2007·European Urology·Axel HeidenreichUNKNOWN European Association of Urology
May 16, 2007·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Andreas MeyerStefan Machtens
Apr 17, 2015·Radiation Oncology·Simon ZuberDaniel R Zwahlen
May 7, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Rikiya TaokaShingo Yamamoto
Oct 24, 2014·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Harun BadakhshiPeter Wust
May 29, 2014·Korean journal of urology·Masahito KidoShin Egawa
Jun 20, 2016·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·J-M CossetL Chauveinc
Oct 21, 2016·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Pieter LoggheLuc Merckx
Oct 19, 2007·Der Radiologe·T F JakobsT K Helmberger
Aug 7, 2020·Physics in Medicine and Biology·Taylah Jane BrennenMarco Petasecca

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.